Our work delivers crucial molecular evidence for understanding EDs-driven cancer mechanisms and proposes targeting the EDs-PLK1 axis as a viable chemo-preventive and therapeutic strategy for prostate cancer. This evidence concerns the gene PLK1 and Familial prostate cancer.